PRMT1 and glioblastoma: Our growth-inhibitory results align with reports of MS023 sensitivity in a subset of colorectal cancer organoids and human-derived glioblastoma stem cell lines39,40, which provide additional models to assess the dependency toward the innate immune response for sensitivity to PRMT1 inhibitors, such as MS023, but the underlying mechanisms were not investigated.